Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Change in Account Payables (2019 - 2025)

Fulcrum Therapeutics (FULC) has disclosed Change in Account Payables for 7 consecutive years, with -$1.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Account Payables rose 59.03% to -$1.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $428000.0, a 126.87% increase, with the full-year FY2025 number at $428000.0, up 126.87% from a year prior.
  • Change in Account Payables was -$1.1 million for Q4 2025 at Fulcrum Therapeutics, down from $946000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $1.2 million in Q4 2021 to a low of -$2.7 million in Q4 2024.
  • A 5-year average of -$111050.0 and a median of $125500.0 in 2023 define the central range for Change in Account Payables.
  • Peak YoY movement for Change in Account Payables: tumbled 4357.14% in 2021, then surged 1150.0% in 2024.
  • Fulcrum Therapeutics' Change in Account Payables stood at $1.2 million in 2021, then fell by 23.21% to $903000.0 in 2022, then plummeted by 190.48% to -$817000.0 in 2023, then tumbled by 230.11% to -$2.7 million in 2024, then surged by 59.03% to -$1.1 million in 2025.
  • Per Business Quant, the three most recent readings for FULC's Change in Account Payables are -$1.1 million (Q4 2025), $946000.0 (Q3 2025), and $244000.0 (Q2 2025).